Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults
European Journal of Pharmaceutical Sciences · 2023
DOI: 10.1016/j.ejps.2023.106376 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2023. Verfasst von Jie En Valerie Sia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Geriatrics Department, Peking University Third Hospital, Beijing 100191, China; Drug Clinical Trial Center, Peking University Third Hospital, Beijing…. Hauptthemen laut MEDLINE: Dabigatran, Rivaroxaban. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation, National Natural Science Foundation of China.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Drug-drug interaction (DDI) is one of the major concerns for the clinical use of NOACs in the older adults considering that coexistence of multiple diseases and comorbidity were common. Current guidelines on the DDI management were established based on clinical studies conducted in healthy adults and mainly focus on the Caucasians, whereas systemic and ethnic differences may lead to distinct management in the Chinese older adults. OBJECTIVES: To investigate the impact of aging on the DDI magnitude between P-gp and/or CYP3A4 inhibitors with dabigatran etexilate and rivaroxaban in older adults, providing additional information for the use in clinical practice. RESULTS: Compared with the simulated adult, the AUC of the simulated older adults increased by 42-88% (DABE) and 21-60% (rivaroxaban), respectively, during NOACs monotherapy. Simulation on DDIs predicted that verapamil and clarithromycin further increase the exposure of dabigatran by 29-72% and 40-47%, whereas clarithromycin, fluconazole, and ketoconazole increase the exposure of rivaroxaban by 21-30%, 16-24%, and 194-247% in the older adults. Overall, our simulation result demonstrated that aging and DDIs both increased the exposure of NOACs. However, aging does not have a drastic impact on the extent of DDIs. The DDI ratios of young and old older adults were similar to the adults and were also similar between Caucasians and Chinese. DISCUSSION: We further simulated the interactions under steady-state based on the EHRA guideline (2021). Our simulation results revealed that recommended reduced dosing regimen of dabigatran etexilate during comedication with verapamil and clarithromycin (110 and 75 mg BID for Chinese young and old older adults) will result in exposure (trough concentration) that was either slightly higher or similar to the trough concentration of patients with any bleeding events. Routine monitoring of bleeding risk is encouraged. Further studies on the use of rivaroxaban in Chinese older adults are warranted. CONCLUSION: Aging and DDI increases exposure of drug in Chinese older adults. However, aging does not have a drastic impact on the extent of DDIs. Clinical management of DDIs in Chinese older adults in the absence of complex polypharmacy can a priori be similar to the EHRA guideline but routine monitoring of bleeding risk is encouraged when dabigatran etexilate given with verapamil and clarithromycin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Geriatrics Department, Peking University Third Hospital, Beijing 100191, China; Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China; Department of Clinical Pharmacy and Pharmacy Administr…
- Geriatrics Department, Peking University Third Hospital, Beijing 100191, China.
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, C…
- Geriatrics Department, Peking University Third Hospital, Beijing 100191, China; Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China; Center of Clinical Medical Research, Institute of Medi…
Förderung
- Bill and Melinda Gates Foundation
- National Natural Science Foundation of China
Zitieren
APA
Sia, J. E. V., Lai, X., Wu, X., Zhang, F., Li, H., Cui, C., & Liu, D. (2023). Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2023.106376
Vancouver
Sia JEV, Lai X, Wu X, Zhang F, Li H, Cui C, et al. Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults. European Journal of Pharmaceutical Sciences. 2023. doi:10.1016/j.ejps.2023.106376
BibTeX
@article{Sia2023,
author = {Sia, Jie En Valerie and Lai, Xuan and Wu, Xinyi and Zhang, Fan and Li, Haiyan and Cui, Cheng and Liu, Dongyang},
title = {Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults},
journal = {European Journal of Pharmaceutical Sciences},
year = {2023},
doi = {10.1016/j.ejps.2023.106376}
}
EUVIMED